Last reviewed · How we verify
NCT06443021: pPD
Investigation of the Influence of Variable Fill Volume, Dwell Duration and Dialysis Fluid Glucose Composition on Measured Ultrafiltration Volume (UFV) in Automated Peritoneal Dialysis (APD) Patients
NA trial testing PD cycler in Renal Failure. Withdrawn.
1 October 2025
Quick facts
| Lead sponsor | Fresenius Medical Care Deutschland GmbH |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Start date | 1 October 2025 |
| Primary completion | 1 October 2025 |
| Estimated completion | 1 December 2025 |
Drugs / interventions tested
- PD cycler
Conditions studied
- Renal Failure — all drugs for Renal Failure →
- Chronic Kidney Diseases — all drugs for Chronic Kidney Diseases →
Sponsor
Fresenius Medical Care Deutschland GmbH — full company profile →
Who can join
18 and older, any sex, with Renal Failure or Chronic Kidney Diseases. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Ultrafiltration volume (UFV)
Time frame: every day during the 11 weeks treatment
UFV determined per defined dwells with variable dwell duration, dialysis fluid glucose composition and inflow volumes.
Sponsor's own description
The purpose of the current investigation is to provide proof of concept for a future approach to improve UF prediction accuracy. While building on the ideas of the past, the concept is augmented by leveraging additional diagnostic technologies and digital data analytics methodologies.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06443021
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Renal Failure
Currently open trials in the same condition.
- NCT07293936 — Post-Filter Hematocrit · NA · recruiting
- NCT06814327 — Assessment of Organ Failure Risk Predictions in ICU · active not recruiting
- NCT06203977 — Inflammation REduction to Prevent cArdiovascular Injury in Renal Disease (REPAIR) · Phase 1 · recruiting
- NCT06142396 — Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure · EARLY_PHASE1 · recruiting
- NCT06620523 — Prevent Cardiac Surgery Associated AKI Trial · Phase 2 · recruiting
Other Fresenius Medical Care Deutschland GmbH trials
Trials by the same sponsor.
- NCT06236984 — Retrospective Data Analysis of CKRT (Continuous Kidney Replacement Therapy) Treatments in Adult Mode With multiFiltrateP · completed
- NCT05441020 — Development, Feasibility Testing and Validation of a Survey Set to Measure Patient-Reported Outcomes Among Hemodialysis · completed
- NCT05315817 — Safety and Performance Evaluation of multiPlus Dialysate During CRRT · NA · terminated
- NCT05142501 — Observation of the Immune Response After COVID-19 Additional Vaccine Doses in Chronic Patients in Hemodialysis Therapy · terminated
- NCT04871893 — Safety and Efficacy Evaluation of CO2 Removal in Combination With Continuous Veno-Venous Hemodialysis/Hemodiafiltration · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06443021 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fresenius Medical Care Deutschland GmbH
- Last refreshed: 16 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06443021.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing